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Abstract 
BACKGROUND: The role of sarcopenia and dynapenia in disability in older persons from falls and bone health 
clinics remain unknown. 
AIM: This study aims to compare the association of sarcopenia and dynapenia with physical and instrumental 
disability in a population of older persons attending a falls and fractures clinic.  
METHODS: This is a cross-sectional study in Manizales, Andes Mountains, Colombia.  A cohort of 534 subjects 
(mean age = 74, 75% female) Sarcopenia was measured according to the European Working Group on 
Sarcopenia in Older People (EWGSOP) including an index of skeletal mass, muscle strength, and gait speed. 
Dynapenia was defined as a handgrip force ≤ 30 kg for men and ≤ 20 kg for women.  
RESULTS: Dynapenia and sarcopenia were present in 84.6% and 71.2% respectively. Both were more prevalent 
in older subjects and women than men.  While sarcopenia was associated with body mass index and 
hypertension, dynapenia was associated with hypothyroidism and visual impairment.  After controlling for all 
covariates, sarcopenia was associated with low IADL and mobility disability.  
CONCLUSIONS: Sarcopenia was associated with mobility, ADL and IADL disability. Dynapenia was not 
associated with disability in this high - risk population. Systematic assessment of sarcopenia should be 
implemented in falls and fractures clinics to identify sarcopenia and develop interventions to prevent functional 
decline among elderly individuals. 
 
 
 
 
 
Introduction 
 
Sarcopenia has been defined as a loss of 
muscle mass and muscle strength related to ageing. 
[1][2]. However, there are divergences about the 
mechanisms, definitions and measurements of 
sarcopenia. The main point of discussion is the 
inclusion of muscle mass and strength in the same 
concept because the decline in muscle strength can 
be attributed to a combination of muscular and neural 
factors and not only to reduced muscle mass [3]. At 
the same time, recent data from longitudinal studies 
on ageing indicate that maintaining or gaining muscle 
mass does not prevent aging-related decline in 
muscle strength [4][5]. Dynapenia (Greek translation 
for the poverty of strength, power, or force) is the age-
associated loss of muscle strength that is not caused 
by neurologic or muscular diseases [6]. Low muscle 
strength is well known to place older adults at an 
increased risk of mobility limitations and mortality [6]. 
Accordingly, the preservation of muscle strength and 
power with advancing age is of high clinical 
significance. 
Since dynapenia is only partially explained by 
the reduction in muscle mass (sarcopenia), several 
authors insist that these two conditions need to be 
defined independently of one another [7]. However, 
The European Working Group on Sarcopenia in Older 
People (EWGSOP) recommendations for a diagnosis 
of sarcopenia, which is widely disseminated in clinical 
practice, includes not only the presence of low muscle 
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mass (LMM) but also low muscle strength (LMS) 
and/or low physical performance (LPP) [8]. Recent 
studies have highlighted the relationship between 
sarcopenia and falling [9][10]. Indeed, we previously 
identified a phenotype of osteosarcopenia in older 
individuals with a history of falling in a fall and 
Fractures Clinic in Australia [11]. However, the role of 
sarcopenia and dynapenia in disability in this high-risk 
population remains unexplored. 
Also, few studies have been carried on in 
Latin America about sarcopenia o dynapenia as a 
predictor of disability [12][13].  
Therefore, the present study aims to compare 
the association of disability with either EWGSOP - 
defined sarcopenia or dynapenia in a high - risk 
population of older fallers in Colombia.  
 
 
Materials and Methods 
 
Study population 
This is cross-sectional study. The setting was 
the Falls, Dizziness, and Fractures Clinic at University 
of Caldas (Manizales, Andes Mountains, Colombia, 
South America). The participants were 534 subjects 
(mean age = 74, 75% female) assessed between 
January 2002 - 2014. To be included in the study, 
participants had to be at least 60 years old and have a 
complete data set. Participants were excluded based 
on severe medical conditions that may significantly 
affect their mobility or incomplete registration of data.  
Eligibility criteria to attend the falls, dizziness 
and fractures clinic included ability to mobilize with a 
walker or cane(s), willingness to attend the clinic, and 
at least one of the following: multiple faller (more than 
two in the last year), single faller with established gait 
and/or balance problem (e.g., by Get Up and Go 
Test), unexplained fall with apparent complex medical 
cause(s), history of chronic dizziness (last 5 years and 
no earlier than 3 months) and/or history of self -
reported symptomatic or asymptomatic fragility 
fracture(s). The University of Caldas Ethics Research 
Committee approved this study. 
 
Dependent variables: disability  
Respondents were asked if they had difficulty 
performing activities of daily living (ADL) using a 
Spanish version of the Barthel ADL scale [14]. If the 
respondents indicated difficulty or inability in 
performing one or more of the tasks, they were scored 
as having ADL disability. Despite its importance about 
functionality in elderly individuals, incontinence was 
not included in ADL because it does not necessarily 
imply physical limitation [15]. For the instrumental 
activities of daily living (IADL), respondents were 
asked if they were able to perform eight activities 
(using a telephone, shopping, preparing meals, 
performing light housework, taking medications, 
managing money, doing heavy housework and using 
transportation), using a modified Spanish version of 
the Lawton IADL scale [16]. If respondents indicated 
difficulty or inability in performing one or more of the 
tasks, they were scored as having IADL disability. A 
summary score for mobility, ADL and IADL variables 
was computed. The final disability variable was 
hierarchical, with three levels. A score of 0 indicated 
no mobility, ADL or IADL limitation; 1 indicated any 
IADL limitation or a mobility limitation, and 2 indicated 
IADL and ADL limitations [17]. 
 
Independent Variables 
Muscle mass was estimated by appendicular 
skeletal muscle mass (ASM) using the Lee equation 
as follow [18]: ASM = (0.244 * body weight) + (7.8 * 
height) + (6.6 * gender) – (0.098 * age) + (race – 3.3). 
Body weight was measured in kilograms (kg), and 
height was measured in meters. This equation has 
been validated in older population from Latin America 
using dual-energy X-ray absorptiometry (DXA) as a 
gold standard with a high correlation between 
methods (r = 0.86 for men and r = 0.90 for women, 
respectively, p < 0.05) [19]. After estimating the 
values, we adjusted the ASM by height squared to 
create the skeletal muscle mass index (SMI). 
Following the studies of Delmonico et al. [20] 
and Newman et al. [21], the cutoff for LMM used was 
based on the 20% lowest percentile of the population 
distribution, representing SMI of ≤ 6.37 kg/m
2
 for 
women and ≤ 8.90 kg/m
2
 for men. Muscle strength 
was assessed with handgrip strength in kg using a 
hand-held dynamometer (Takey hydraulic 
dynamometer, the Smedley Hand Dynamometer III). 
Grip size was adjustable so that each participant felt 
comfortable while squeezing the grip. The test was 
performed twice in the dominant limb with a 1 - minute 
rest between tests and the higher value of the two 
trials was used for scoring. Cutoff values of < 30 kg for 
men and < 20 kg for women were considered to 
represent Low Muscle Strength [8][22]. 
The Spanish validated the version of Physical 
performance was assessed with gait speed (in 
meters/second), determined using the walk test of the 
Short Physical Performance Battery assessing Lower 
Extremity Function. The faster of the two trials was 
used for analyses [23]. The cut - off point of ≤ 0.8 m/s 
was used to represent LPP [8][22]. 
Sarcopenia was defined using the EWGSOP 
criteria. Participants with LMM plus either LMS or LPP 
were considered as having sarcopenia [8]. Dynapenia 
was defined using the criteria of Laurentani et al. [22]: 
< 30 kg for men and < 20 kg for women. 
 
Clinical Science 
_______________________________________________________________________________________________________________________________ 
 
_______________________________________________________________________________________________________________________________ 
346                                                                                                                                                                                                https://www.id-press.eu/mjms/index 
 
Covariates 
Demographic characteristics were age, 
gender, marital status and education. Education was 
measured as years of formal schooling completed and 
was analysed as a continuous variable. (range, 0 to 
18). Health status variables included perceived health 
status, chronic conditions, visual and auditory 
impairment, depression and cognitive status. The 
presence of seven chronic conditions (osteoarthritis, 
hypertension, diabetes mellitus, stroke, chronic 
obstructive pulmonary disease, and hypothyroidism) 
was ascertained through self - report. Physical 
performance was assessed with gait speed (in 
meters/second), determined using the walk test of the 
Short Physical Performance Battery Assessing Lower 
Extremity Function [23]. The faster of the two trials 
was used for analyses. The cut - off point of ≤ 0.8 m/s 
was used to represent LPP [8]. Falls and 
hospitalisations in the previous 12 months were 
assessed. Sensory impairments were assessed by 
asking for troubles with vision and hearing (yes or no). 
Cognition was assessed by the Mini-Mental State 
Examination; participants with a score of less than 20 
were considered to be cognitively impaired [24][25]. 
An abbreviated (score 0 to 15) Spanish-validated 
Geriatric Depression Scale (GDS - S) was used to 
assess the presence of depressive symptoms [26]; 
respondents with a score of 6 or more on GDS - S are 
considered likely to be depressed. Body mass index 
(BMI) was computed by dividing weight in kilograms 
by height in square meters (kg/m
2
). 
 
Statistical analyses  
The characteristics of the participants were 
described by means and standard deviations (SD) or 
frequencies and percentages according to the type of 
variable (continuous or categorical, respectively). The 
chi-square test was used to test qualitative data, while 
analysis of variance (ANOVA) was used to evaluate 
continuous data. Statistical differences between 
groups were determined. To identify the factors 
associated with disability, variables were selected 
based on the strength of the associations, higher 
prevalence (10% or more), clinical relevance, and low 
potential for collinearity. We calculated OR and 95% 
confidence intervals (CI). A three-step procedure was 
developed. First, univariate logistic regression 
analyses were used to describe the unadjusted effect 
of sarcopenia and dynapenia and covariates, in the 
second step, multivariate linear regression models 
were created to adjust by potential confounder 
covariates. Based on previous results, we proceeded 
with multivariate analysis using multiple multinomial 
logistic regressions, which estimates the prevalence 
odds ratios (OR). Model 1 includes sarcopenia as an 
independent variable and model 2 includes 
dynapenia. Statistical analyses were performed using 
SPSS for Windows version 22.0. 
 
Results 
 
The mean age ± standard deviation of the 
participants was 74.4 ± 8.2 years; 75.5% were female, 
41.1% were married and the mean years of scholarly 
were 6.2 ± 4.4. The most prevalent medical conditions 
were hypertension (65.9%), hypothyroidism (21.9%) 
and diabetes (15.5%). Sarcopenia and dynapenia 
were present in 84.6% and 71.2% of the participants, 
respectively. Table 1 shows the baseline 
characteristics of the total sample and by sarcopenia 
and dynapenia status. Participants with sarcopenia 
and dynapenia were significantly more likely to be 
older. Those with dynapenia were more female and 
reported more hypothyroidism, falls and visual 
impairments, while those with sarcopenia had lower 
BMI and reported more hypertension. Visual and 
auditory impairments were reported by 80.4 % and 
49.3% of the participants, respectively.  
Table 1: Characteristics of the total sample and by sarcopenia 
and dynapenia status at baseline in clinic of fractures, falls and 
dizziness 
Characteristic 
Total sample 
N = 534 
No 
Sarcopenia 
N = 154 
(15.4) 
Yes 
Sarcopenia 
N = 380 
(84.6) 
Yes 
Dynapenia 
N =  452 
(71.2) 
No 
Dynapenia 
N =  82 
(28.8) 
Sociodemographics   
 Age, mean (DE) 74.4 (8.2) 74 (7.9)* 76 (8.3)* 75.9 (8.1) ** 72.6 (8.6) ** 
 80 or more years (%) 173 (32.4) 42 (27.3) 131 (34.5) 156 (34.5) 17 (20.7) 
 Women (%) 403 (75.5) 117 (76) 286 (75.3) 364 (80.5)** 39 (47.6)** 
 Schooling (years) 
(Mean DE) 
6.24 (4.4) 5.9 (4.2) 
6.4 (4.5) 6.4 (4.4)* 
5.5 (4.4)* 
Marital status (single) 
(%) 
77 (14.4) 15 (9.7) 
62 (16.3) 72 (15.9) 
5 (6.1) 
Self perceived health 
 Bad /very bad (%) 
73 (13.8) 22 (14.2) 
51 (13.6) 61 (13.7) 
12 (14.6) 
Health conditions 
 Hipertension (yes) 344 (65.9) 114 (75)** 230 (62.2)** 294 (66.5) 50 (62.5) 
 Cancer  26 (5) 8 (5.3) 18 (4.9) 23 (5.2) 3 (3.8) 
 Stroke 43 (8.4) 18 (12.1) 25 (6.9) 39 (9) 4 (5) 
 Diabetes (yes) 81 (15.5) 31 (20.3) 50 (13.5) 73 (16.4) 8 (10) 
 Osteoartritis (yes) 33 (6.3) 8 (5.3) 25 (6.7) 29 (6.5) 4 (5) 
 Hipothiroidism 115 (21.9) 42 (27.5) 73 (19.7) 108 (24.3) ** 7 (8.8) ** 
COPD 55 (10.7) 13 (8.7) 42 (11.4) 48 (11) 7 (8.8) 
 Falls in last year (yes) 309 (60.4) 216 (59.5) 93 (62.4) 261 (72.7)* 38 (47.5)* 
 Hospitalization last year 
(yes) 
289 (54.1) 80 (51.9) 
209 (55) 246 (54.4) 
43 (52.4) 
Vision impairment (yes) 426 (80.4) 122 (79.7) 304 (80.6) 370 (82.4) ** 56 (69.1) ** 
 Hearing impairment 
(yes) 
255 (49.3) 76 (50.7) 
179 (48.8) 207 (47.4)* 
48 (60)* 
 BMI: mean (DE) 26 (7.1) 30.3 (6.7) ** 24.2 (6.4) ** 25.6 (7.06) 28 (6.9) 
Cognitive status  
 MMSE < 20 (%) 
66 (12.4 ) 14 (9.1) 
52 (13.7) 59 (13.1) 
7 (8.5) 
Depressive symptoms 
GDS > 5 (n %) 
233 (43.4) 76 (49.4) 156 (41.1) 205 (45.4) 27 (32.9) 
Physical performance 
(SPPB) 
Gait Speed (M/seg). 
mean (DE)  
0,80 (0.99) 0.91 (1.15)** 0.54(0.17)** 0.73 (0.62)* 1.18 (2.03)* 
* P<0.05; **P<0.01. 
 
In the bivariate analysis, there were strong 
associations between dynapenia and age (OR = 1.06, 
95% CI = 1.01 - 1.11, p = 0.01), sex (OR = 1.16, 95% 
CI=1.16 - 1.31, P < 0.01), hypothirodism (OR = 6.09, 
95% CI = 1.56 – 23.7, p < 0.01) and visual impairment 
(OR = 2.21 (1.03 - 4.75, p < 0.01). While significant 
associations were noted between sarcopenia and age 
(OR = 1.04, 95% CI = 1.0 - 1.08, p < 0.01), sex (OR = 
1.37, 95% CI = 1.00 – 2.51, p = 0.29) and BMI (OR = 
1.02, 95% CI = 1.0 – 1.09, p < 0.01).  
Table 2 presents the weighted multinomial 
regression analysis for disability. In model 1, the 
following were risk factors for incidence in mobility or 
IADL disability: age and sarcopenia; some falls had a 
marginal statistical relationship. The risk factors for 
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ADL and IADL disability were: age, female and 
sarcopenia. In model 2 the same risk factors were 
found. However, dynapenia was not associated with 
disability. 
Table 2: Weighted multinomial regression analysis for 
disability 
 Mobility or IADL 
Sarcopenia 
model 
N = 259 
OR (95%) 
ADL and IADL 
Sarcopenia 
model 
n= 144 
OR (95%) 
Mobility or 
IADL 
Dynapenia 
model 
n= 332 
OR (95%) 
ADL and IADL 
Dynapenia 
model 
n= 192 
OR (95%) 
Age 1.09 
(1.05–1.11) 
1.12  
(1.08 – 1.16) 
1.08  
(1.05-1.12) 
1.11  
(1.08 – 1.15) 
Sex (female) 1.50 
(0.87 – 2.58) 
2.29  
(1.32 – 3.96) 
1.43  
(0.81 – 2.52) 
1.97  
(1.11 – 3.49) 
Hypertension  0.67 
(0.40 – 1.12) 
0.78  
(0.48 – 1.27) 
0.63  
(0.38 – 1.04) 
0.71  
(0.43 – 1.15) 
Hypothyroidism 1.52 
(0.83– 2.80) 
1.15  
(0.65 – 2.03) 
1.45  
(0.79 – 2.66) 
1.13  
(0.64 – 1.98) 
Falls (number) 1.01  
(0.93- 1.11) 
1.06  
(0.98 – 1.14) 
1.02  
(0.94 – 1.11) 
1.06  
(0.98 – 1.15) 
Visual impairment 1.24  
(0.69 – 2.23) 
0.70  
(0.30 – 1.65) 
1.34  
(0.74 – 2.42) 
1.29  
(0.71 – 2.33) 
Sarcopenia 2.03  
(1.16 - 3.53) 
2.03  
(1.18 – 3.50) 
- - 
Dynapenia  - - 0.87  
(0.45-1.67) 
0.52  
(0.26 – 1.06) 
 
 
 
Discussion  
 
Sarcopenia, according to the EWGSOP, was 
associated with low mobility and disability. Our data 
correspond with those previous reports [12][27] by 
showing an association between LMM, LMS and LPP 
and IADL, mobility and ADL disability. In addition, 
studies in different settings as community-dwelling 
older people [28][29][30][31][32][33][34][35][36], acute 
care [37][38][39] and nursing homes [40][41] showed 
a significant association between sarcopenia and 
functional limitation and disability.  
Our results also correspond with other studies 
in Latin America, which have demonstrated that 
sarcopenia is a risk factor for disability in the elderly. 
In a four year prospective study in 478 individuals 
from SABE study, founded after controlling for all 
covariates, Aleixandre et al., reported that sarcopenia 
was associated with mobility or IADL disability [12]. 
Similar to our results, dynapenia was not associated 
with disability. In another cross-sectional study in 90 
hospitalised women in Mexico City, Velasquez - Alba 
et al., reported that sarcopenia was associated with 
difficulties in mobility, particular difficulties in climbing 
stairs [42].  
To the best of our knowledge, this is the first 
paper testing the role of sarcopenia in the clinical 
measurements performed at falls and fractures clinics. 
The prevalence of sarcopenia is difficult to establish. 
The percentage of sarcopenia (84.6%) found in our 
study is higher than reported for older people living in 
the community (1-29%), for those living in long-term 
care institutions (14-33% and up to 68% in men), and 
for those in acute hospital care 10% [43]. In another 
study about of sarcopenia in geriatric outpatient 
clinics, a prevalence of sarcopenia was higher in 
women (22.9%) than in men (12.7%) [44]. Indeed, this 
prevalence can differ depending on the characteristics 
of the studied population and the cut off applied for 
measuring [45]. Our sample had a mean walk speed 
of 0.8 mt/sec and cut off point for EWGSOP criteria by 
sarcopenia case finding [8]. Another possible reason 
is the eligibility criteria of the sample, with complex 
medical problems, chronic dizziness and symptomatic 
or asymptomatic fragility fracture(s). Furthermore, 
muscle mass reflects ethnicity and lifestyle 
characteristics [32]. As a consequence, more data are 
required to determine standardised cut - off values for 
sarcopenia in falls and fracture clinics. However, the 
findings here and elsewhere [27][28][29] support the 
view that intervention strategies designed to preserve 
skeletal muscle mass should be initiated in all older 
people attending falls and fracture clinics.  
Sarcopenia as a risk factor for falls in elderly 
individuals remains controversial. In this study, we 
could not find an association between sarcopenia 
(based on muscle mass) and fall number in the last 
year. There are conflicting reports regarding the 
relationship of sarcopenia with fall. Our findings are in 
agreement with the results of several cross-sectional 
surveys on sarcopenia [27][28], but other study using 
EWGSOP criteria examined 260 individuals aged 80 
years or older in Italy found that sarcopenic individuals 
had a high risk of fall incidents compared with non-
sarcopenic individuals [46] Another study in Japan 
with the same criteria examined 1160 individuals aged 
65 years or older revealed that sarcopenia was 
significantly associated with a history of fall [9].  
This study has some limitations. First, the use 
of the use of the regression equation to estimate 
muscle mass may overestimate the prevalence of 
sarcopenia. The availability of DXA as “gold standard” 
for measuring sarcopenia is limited in coffee grower 
zones in Colombian Andes Mountains. However, this 
equation has been used previously in assessing Latin 
American populations [18][19]. Second, the study 
design was cross-sectional, and the results do not 
establish cause-effect relationships between 
sarcopenia and disability and falls. Theoretically, 
certain types of morbidity (e.g., lung disease, stroke, 
and uncontrolled noninsulin - dependent diabetes 
mellitus) could produce sarcopenia that would result in 
functional impairment and disability. It is also possible 
that disability could lead to sarcopenia by limiting 
physical activity and subsequently predisposing 
people to some chronic diseases. Also, none of the 
chronic diseases was significantly associated with 
sarcopenia, except hypertension. Third, we used 
handgrip strength and usual walking speed cutoff 
values that were based on values derived from other 
reference population. Future studies are required to 
determine the optimal muscle strength and physical 
performance cutoff values for defining sarcopenia on 
this population.  
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This study has several strengths. First, it was 
conducted on a large sample of patients comes from 
falls, dizziness and fractures clinic in Latin America. 
Second, this study is the first to analyse sarcopenia 
using the EWGSOP criteria at a falls, dizziness and 
fracture clinic and to compare this method with 
dynapenia as a risk factor for mobility, IADL, disability 
and ADL disability.  
In conclusion, sarcopenia is a risk factor for 
developing IADL, mobility and ADL disabilities in older 
people. The diagnostic criteria from (EWGSOP) using 
normative data should be implemented at falls and 
fractures clinics to identify sarcopenia and develop 
early interventions to prevent functional decline 
among this population of high-risk elderly individuals. 
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